title: [Intra-arterial cellular immunochemotherapy for unresectable pancreatic cancer with liver metastasis].
abstract: OBJECTIVE
  To date, no treatment has had a significant impact on pancreatic cancer with liver metastasis. We performed locoregional cellular immunochemotherapy for unresectable pancreatic cancer with liver metastasis.
  
  
  METHODS
  A 71-year-old man was diagnosed for unresectable stage IVb pancreatic cancer. This patient was given intra-arterial infusion of gemcitabine (GEM) 400 mg/body and intravenous infusion GEM 600 mg/body, simultaneously. The day after GEM infusion, he was given intra-arterial autologous tumor cell activated T lymphocytes (AuTL).
  
  
  RESULTS
  Tumor markers, such as CEA and CA19-9, had decreased a little. Primary tumor and metastatic liver tumor were reduced, but he died due to intra-abdominal dissemination within 5 months after diagnosis of unresectable pancreatic cancer.
  
  
  CONCLUSIONS
  Reduced primary pancreatic tumor and metastatic liver tumor was obtained by locoregional cellular immunochemotherapy. But we could not control intra-abdominal dissemination. In conclusion, we suggest that intra-abdominal AuLT infusion in combination with intra-arterial AuLT infusion may be advisable to patients for unresectable pancreatic carcinoma with intra-abdominal dissemination.
authors.affiliation: Dept. of Surgery, Kurume University, School of Medicine.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Horiuchi
authors.forename: Uhi
authors.initials: U
authors.lastname: Toh
authors.forename: Shinji
authors.initials: S
authors.lastname: Uchida
authors.forename: Katsumi
authors.initials: K
authors.lastname: Hayashi
authors.forename: Hisafumi
authors.initials: H
authors.lastname: Kinoshita
authors.forename: Hideaki
authors.initials: H
authors.lastname: Yamana
authors.forename: Shigeaki
authors.initials: S
authors.lastname: Aoyagi
authors.forename: Kazuo
authors.initials: K
authors.lastname: Shirouzu
authors.forename: Masamichi
authors.initials: M
authors.lastname: Koganemaru
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D014408:Biomarkers, Tumor; D001804:Blood Transfusion, Autologous; D003841:Deoxycytidine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D006801:Humans; D007261:Infusions, Intra-Arterial; D007262:Infusions, Intravenous; D007694:Killer Cells, Natural / Q000276:immunology / Q000637:transplantation*; D008113:Liver Neoplasms / Q000556:secondary*; D008297:Male; D010190:Pancreatic Neoplasms / Q000473:pathology* / Q000628:therapy*; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D003841:Deoxycytidine; D000093542:Gemcitabine